MariMed Inc. (OTCMKTS:MRMD) Short Interest Down 81.7% in January

MariMed Inc. (OTCMKTS:MRMD) was the target of a significant decline in short interest in January. As of January 15th, there was short interest totaling 1,025 shares, a decline of 81.7% from the December 31st total of 5,595 shares. Based on an average trading volume of 945,496 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the company’s stock are short sold. Approximately 0.0% of the company’s stock are short sold. Based on an average trading volume of 945,496 shares, the short-interest ratio is currently 0.0 days.

MariMed Price Performance

OTCMKTS MRMD remained flat at $0.09 during trading hours on Tuesday. The company had a trading volume of 370,836 shares, compared to its average volume of 502,946. The stock has a 50 day moving average price of $0.09 and a 200 day moving average price of $0.12. The company has a debt-to-equity ratio of 1.34, a quick ratio of 0.35 and a current ratio of 1.06. The company has a market capitalization of $34.42 million, a P/E ratio of -2.18 and a beta of 1.04. MariMed has a 52 week low of $0.07 and a 52 week high of $0.23.

MariMed (OTCMKTS:MRMD) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.01) earnings per share for the quarter, meeting the consensus estimate of ($0.01). MariMed had a negative net margin of 11.36% and a negative return on equity of 14.67%. The firm had revenue of $40.76 million during the quarter, compared to analysts’ expectations of $42.15 million.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on MRMD shares. Zacks Research upgraded shares of MariMed from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Ventum Cap Mkts lowered MariMed from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, MariMed has a consensus rating of “Moderate Buy”.

MariMed Company Profile

MariMed Inc is a multi‐state cannabis company focused on the development, ownership and operation of regulated facilities for the medical and adult‐use cannabis markets. Headquartered in New Bedford, Massachusetts, the company cultivates, processes and dispenses cannabis through an integrated business model that encompasses cultivation, formulation, manufacturing and retail operations. MariMed operates under its own licensed brands and through strategic partnerships to expand its presence across the United States.

The company’s product portfolio includes branded flower, pre‐rolls, vaporizer cartridges, tinctures, edibles and topicals designed to meet a range of consumer and patient needs.